Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma

Aasia Ghazi, Anita Trikha, William Calhoun

Research output: Contribution to journalArticle

94 Scopus citations


Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalExpert Opinion on Biological Therapy
Issue number1
StatePublished - Jan 2012



  • Asthma
  • Benralizumab
  • IL-5
  • IL-5Rα
  • MEDI-563

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this